The use of posttransplant cyclophosphamide (PT-Cy) has contributed significantly to the success of haploidentical hematopoietic cell transplantation (HCT). Furthermore, several studies have shown promising results in the human leukocyte antigenmatched setting. However, the use of high-dose cyclophosphamide has been associated with the development of cardiomyopathy. There is a paucity of data concerning posttransplant cardiac complications in patients undergoing PT-Cy-based HCT. METHODS: A retrospective analysis of 176 patients undergoing HCT with PT-Cy was performed. The overall survival, left ventricular ejection fractions, brain natriuretic peptide levels, and cardiac comorbidities were reviewed. The associations between comorbidities and the onset of heart failure were assessed with a Cox proportional hazards model. RESULTS: Pretransplant cardiomyopathy was found in 16 patients (9.1%) but had no effect on their posttransplant overall survival. Thirty-five patients (21.9%) developed posttransplant cardiomyopathy, which correlated with increased mortality, but this was not statistically different from the frequency-matched non-PT-Cy cohort. The majority of these cardiomyopathies occurred in the setting of an infectious milieu. An age greater than 60 years and an HCT comorbidity index score equal to or greater than 4 were the only risk factors that correlated with posttransplant cardiomyopathy. CONCLUSIONS: The presence of pretransplant cardiomyopathy does not negatively affect overall survival for patients who undergo HCT with PT-Cy. Furthermore, cardiomyopathy in PT-Cy patients is not caused by PT-Cy but is mostly concurrent with infectious complications and is associated with reduced overall survival. Traditional cardiovascular risk factors do not fully predict the occurrence of posttransplant cardiomyopathy. Future research is required to unravel predictive factors for cardiomyopathy after PTCy-based HCT.
INTRODUCTION
Hematopoietic cell transplantation (HCT) can be a lifesaving treatment modality for patients with malignant or nonmalignant hematological disorders. 1 Advances in HCT have transformed many historically dire diagnoses into conditions that can be cured or managed. 1 The use of HCT has been limited by the availability of human leukocyte antigen (HLA)-matched donors. Although matched related donors (MRDs) provide the best balance between therapeutic efficacy, rejection, and graft-versus-host disease (GVHD), this option is available only to an estimated 30% of patients requiring transplantation. 2 Although matched unrelated donors (MUDs) represent an alternative donor source, the likelihood of a match varies among ethnic and racial groups: Caucasian patients are substantially more likely to have a fully HLA-matched unrelated donor available (75%) than patients of African (<20%), Asian (<45%), or Hispanic ancestry (<40%). 3 Such obstacles have led to the development of haploidentical HCT protocols, which, by allowing HLA mismatch, expand the pool of potential donors to parents, siblings, and children and provide almost universal availability. 4 However, the increased HLA mismatch can also lead to increased T-cell alloreactivity and cause GVHD. Multiple immunosuppressive, chemotherapeutic, and physical depletive methods have been devised to prevent GVHD. High-dose posttransplant cyclophosphamide (PT-Cy) has emerged as an effective method for preventing GVHD. 5, 6 Promoting tolerance in alloreactive T cells, this platform has been successfully used in MRD, MUD, and haploidentical HCT.
The use of cyclophosphamide has been associated with cardiomyopathy, 8 a well-documented and serious complication after autologous and allogeneic HCT and a leading cause of morbidity and mortality in these patients. 9 Allogeneic (MUD and MRD) HCT survivors have a 2.3-fold increased risk of late death due to cardiac complications in comparison with the general population. 10 Similarly, congestive heart failure/cardiomyopathy has been reported with a prevalence of 2% after a median follow-up of 6 to 7 years in a population of autologous and allogeneic HCT patients. 11 Cardiac events may occur early in the peritransplant phase or late in long-term HCT survivors. 9 The risk for the development and outcome of posttransplant cardiomyopathy depends on a patient's history, age, primary diagnosis, type of transplant, comorbidities, and conditioning regimen. 9 Although Oshima et al 12 reported a heart failure incidence of 57% in a series of 14 haploidentical HCT patients who also received alemtuzumab, the incidence and risk factors of cardiomyopathy in these patients remain largely unclear; this is particularly true for patients treated with the PT-Cy platform. Therefore, we conducted a retrospective analysis of patients who received PT-Cy to define the incidence of cardiomyopathy and associated risk factors in these patients.
MATERIALS AND METHODS

Patients
This study was reviewed and approved by the institutional review board at Barnes-Jewish Hospital/Washington University in St. Louis. A retrospective cohort study was performed in consecutive patients who underwent HCT with PT-Cy between 2009 and 2015 at Barnes-Jewish Hospital/Washington University in St. Louis; the study included 141 haploidentical HCT procedures, 27 MUD procedures, and 11 MRD procedures. Three haploidentical HCT patients received MUD or MRD before or after haploidentical HCT. Another 54 patients who received MRD transplantation without PT-Cy, frequencymatched for age and sex with the PT-Cy cohort, were included as controls. The patient demographics, cardiac comorbidities, disease status, and treatment modality were curated. We reviewed all available cardiac tests, including echocardiograms, nuclear studies, and natriuretic peptide levels (brain natriuretic peptide [BNP] and N-terminal pro-BNP). All patients underwent a pretransplant assessment of their left ventricular ejection fraction (LVEF) with either a radionuclide multigated acquisition scan or echocardiography. Posttransplant echocardiograms, electrocardiograms, and biochemical measurements were obtained on an as-needed basis according to the clinician's discretion. Patients who had pretransplant cardiomyopathy (defined later) were excluded from the analysis for posttransplant cardiomyopathy.
Survival Analysis
A survival analysis was performed with an endpoint of the time to all-cause mortality. Death was ascertained by a review of in-hospital expiration notes, out-of-hospital death certificates, and communications. Patients were censored at the time of their last clinical encounter. The length of survival was defined as the interval between the dates of index transplantation and the last clinical encounter (for living patients) or death (for deceased patients). The first transplant event was used as the index transplant for patients who received 2 transplants with PT-Cy.
Heart Failure Assessment
We reviewed all available cardiac echocardiograms and multigated acquisition scans, and we extracted ejection fractions. In the case of multiple posttransplant studies, those with the lowest LVEF values were reported. In the case of a range (eg, 55%-60%), the mean of the range was used. We defined elevated natriuretic peptides as BNP levels greater than 200 pg/mL or N-terminal pro-BNP levels greater than 2000 pg/mL. 13 We used a cutoff value of 200 pg/mL because it is a commonly used value for patients with a glomerular filtration rate < 60 mL/min (a common occurrence in this population).
14 This cutoff level is in accordance with a previous consensus statement on assessing cardiac dysfunction in the transplant population. 15 We defined diastolic dysfunction as grade 2 or worse on mitral inflow spectral Doppler. The onset time of posttransplant cardiomyopathy was defined as the difference between the date of transplantation and the earlier date of echocardiography or natriuretic peptide levels meeting the cutoff described in the text.
Cardiac Comorbidities
We reviewed all clinical data in the clinical database at Barnes-Jewish Hospital/Washington University in St. Louis. The diagnosis of diabetes was ascertained by the mention of the diagnosis in clinical notes, outpatient use of antidiabetic medications, or a single hemoglobin A 1c level equal to or greater than 6.5%. The diagnosis of hypertension was defined as outpatient use of antihypertensive medications. Dyslipidemia was defined as a lowdensity lipoprotein cholesterol level greater than 130 mg/ dL, a high-density lipoprotein cholesterol level less than 30 mg/dL, or the use of a statin. A history of coronary artery disease was ascertained by the diagnosis in outpatient notes.
Statistics
Statistical analyses were performed with the open-source edition of RStudio (version 0.99.893; RStudio, Inc, Boston, Mass). Chi-square or Fisher exact tests were used for the testing of differences of proportions. A log-rank test was used for survival analysis. A paired Student t test was used to compare LVEFs before and after HCT. Cox proportional hazards analysis was used to model the probability of developing cardiomyopathy as a function of various prognostic covariates, with independent predictors reported as hazard ratios (HRs) with 95% confidence intervals (CIs). All testing was performed in a 2-sided fashion at a significance level of .05.
RESULTS
Patient Characteristics
Between July 2009 and December 2015, 179 HCT procedures were performed with the PT-Cy platform at Washington University in St. Louis. This included 141 patients with haploidentical HCT and 38 patients with matched HCT (27 with MUDs and 11 with MRDs). One patient underwent haploidentical HCT after MRD, another underwent haploidentical HCT after MUD, and yet another underwent haploidentical HCT followed by MUD. Another cohort of 54 patients, who underwent MRD HCT without PT-Cy and were frequency-matched for age and sex to the PT-Cy cohort, were included as controls. The demographics, diagnoses, types of conditioning, and cardiac comorbidities are summarized in Table 1 . The first transplant event was used as the index transplant for the following analyses. As shown in the Kaplan-Meier plot in Figure 1 , the median survival was 243 days with a maximum follow-up of 1842 days and an interquartile interval of 119 to 486 days.
Pretransplant Cardiomyopathy Does Not Affect Overall Survival
We first determined the prevalence of pretransplant cardiomyopathy in our cohort. We defined pretransplant cardiomyopathy as an LVEF depression (45%; n 5 4) or an elevation of BNP (>200 pg/mL; n 5 12) and identified a total of 16 patients (9.1%) with pretransplant cardiomyopathy (Table 1) . Interestingly, there was no statistically significant difference in posttransplant survival between patients with pretransplant cardiomyopathy (n 5 16) and those without it (n 5 160; HR, 0.687; 95% CI, 0.318-1.487; P 5 .338; Fig. 2A ).
The aforementioned definition of cardiomyopathy does not capture heart failure with isolated diastolic dysfunction. To understand whether diastolic dysfunction correlates with survival, we included diastolic dysfunction (defined as diastolic function equal to or worse than grade 2 on spectral Doppler) in a parallel analysis. We identified 6 patients with isolated diastolic dysfunction (LVEF, 55%-70%) and analyzed a total of 22 patients with at least 1 of the following: LVEF 45%, diastolic dysfunction, or BNP level > 200 pg/mL. Similarly, there was no statistically significant difference in survival between these patients (n 5 22) and those without pretransplant cardiomyopathy (n 5 154; HR, 0.794; 95% CI, 0.423-1.494; P 5 .474; Fig. 2B ). Therefore, pretransplant cardiomyopathy or diastolic dysfunction does not affect overall survival after PT-Cy-based HCT.
Reduced LVEF After Transplantation
Among the 176 patients who underwent PT-Cy-based transplantation, 104 (59.1%) underwent echocardiography at some point after the transplant. In the absence of a routine surveillance protocol, these studies were ordered at the treating physician's discretion. In a comparison of only patients who had pretransplant and posttransplant studies, there was a 6.4 percentage-point drop in the mean LVEF measurements (from 62.6% to 56.2%; n 5 104; P 5 .004; Fig. 3A ).
Posttransplant Cardiomyopathy
The finding of reduced LVEF values suggests that some patients may develop cardiomyopathy after transplantation. Patients with preexisting cardiomyopathy (defined as a pretransplant LVEF 45% or BNP level > 200 ng/ mL; Table 1 ) were excluded; this left 160 patients in the following analysis. We adopted the definition of cancer therapeutics-related cardiac dysfunction from the American Society of Echocardiography and the European Society for Cardiovascular Imaging 16 and defined posttransplant systolic dysfunction as a decrease in the LVEF greater than 10 percentage points to a value less than 53%. We then defined posttransplant cardiomyopathy as a composite of posttransplant systolic dysfunction or an elevation of natriuretic peptides. Among the 160 patients who did not have pretransplant cardiomyopathy, 104 underwent echocardiography and/or BNP measurements at some point after transplantation, and 35 (21.9%) were found to have posttransplant cardiomyopathy (Fig. 4) . The demographics of patients who developed posttransplant cardiomyopathy are summarized in Table 2 . The median time to cardiomyopathy detection from transplantation was 85 days with an interquartile range of 20 to 232 days (Fig. 3B) . These patients were treated with guidelinedirected heart failure medications, including b-blockers, inhibitors of the angiotensin activation system, and diuretics as tolerated. The patients who developed posttransplant cardiomyopathy had reduced overall survival in comparison with those who did not (Fig. 3C) . Twenty-one of these patients (60%) died within 1 month of the index cardiomyopathy event. The onset of cardiomyopathy was strongly associated with overall mortality with an HR of 2.37 (95% CI, 1.51-3.73; P 5 .0001). Among the 14 patients (40%) who survived more than 1 month after the index cardiomyopathy event, 9 (64%) subsequently had documented resolution of cardiomyopathy.
We then investigated the circumstances of developing cardiomyopathy. All but 2 (94.3%) developed severe sepsis, septic shock, or neutropenic fever during the index To understand the risk factors for posttransplant cardiomyopathy, we first performed a univariate analysis of individual variables. As shown in Table 2 , the history of diabetes and the HCT-CI score were statistically significant between patients who developed posttransplant cardiomyopathy and those who did not. We next used a multivariate Cox proportional hazards analysis to establish regression models. The 160 patients who did not have pretransplant cardiomyopathy were included in the analysis. We included demographic factors, including age and sex; traditional cardiac risk factors, including hypertension, diabetes, coronary artery disease, and dyslipidemia; and transplant-related variables, including the use of a myeloablative conditioning regimen and total body radiation (TBI). In the first analysis, we chose not to include the HCT-CI score to understand the interaction between individual risk factors because HCT-CI is a comprehensive score encompassing multiple cardiac risk factors. Among these risk factors, the statistically significant risk factors were an age greater than 60 years with an HR of 2.44 (95% CI, 1.144-5.187; P 5 .02) and diabetes with an HR of 2.37 (95% CI, 1.108-5.074; P 5 .03; Table 3 ). Sex, a history of hypertension, coronary artery disease, dyslipidemia, the use of a myeloablative regimen, and TBI were not found to be statistically significant in the prediction of posttransplant heart failure. We next included the HCT-CI score in a separate analysis. As shown in Table 4 , a history of diabetes was no longer statistically significant after the inclusion of the HCT-CI score, which includes a history of diabetes. An age greater than 60 years and an HCT-CI score equal to or greater than 4 were statistically significant predictors of posttransplant cardiomyopathy. Abbreviations: CI, confidence interval; HCT-CI, hematopoietic cell transplantation comorbidity index; HR, hazard ratio; TBI, total body radiation.
Incidence of Pericardial Effusion
There were 24 patients (13.6%) reported with some degree of pericardial effusion, and 17 were small effusions. Among the 7 patients with moderate or more severe pericardial effusion, 2 had a pericardial tamponade physiology on echocardiography, with 1 patient required draining.
Incidence of Posttransplant Cardiomyopathy Similar to That of Patients Without PT-Cy
To delineate the contribution of PT-Cy to posttransplant cardiomyopathy, we used frequency matching (for sex and age at the time of transplantation) to identify a cohort of 54 patients who did not have pretransplant cardiomyopathy and underwent MRD HCT without PT-Cy between 2009 and 2015. As shown in Table 5 , the 2 groups were comparable in age, sex, and cardiac comorbidities. The donor source was significantly different because all patients with haploidentical HCT received PT-Cy. The incidence of posttransplant cardiomyopathy was not found to be statistically significant between patients receiving PT-Cy and those not receiving it (21.9% vs 14.8%; P 5 .33). Therefore, PT-Cy was unlikely to be a major contributor of posttransplant cardiomyopathy.
DISCUSSION
This single-center, retrospective study describes cardiomyopathy in patients receiving PT-Cy-based HCT. To the best of our knowledge, our series is the first specifically investigating the incidence of cardiomyopathy in patients receiving PT-Cy. Also, with 80% of the subjects undergoing haploidentical HCT, this is the largest series to date examining cardiomyopathy in haploidentical HCT patients. An assessment of cardiac function with LVEF is an integral part of the HCT-CI, the most commonly used score for a pretransplant evaluation. 17 The prognostic value of the pretransplant LVEF has been an issue of debate, with some studies but not others showing increased cardiac toxicity in patients with reduced pretransplant LVEF values. 18 A combination of a decreased resting LVEF and its response to exercise correlates with peritransplant mortality in autologous and allogeneic transplant recipients. 19 Recent reports indicate that patients with pretransplant LVEF values less than 45% to 50% can safely undergo allogeneic transplantation without an increase in treatmentrelated mortality, overall survival, or nonrelapse mortality. 20, 21 In the current study, we used existing BNP results to supplement the inclusion of patients with cardiomyopathy. It should be noted that a pretransplant assessment of BNP was not performed per protocol but instead according to the practitioner's clinical judgment. The optional use of BNP for the pretransplant assessment of cardiac function is in accordance with a consensus statement. 15 We identified pretransplant cardiomyopathy (depressed LVEF [45%] or elevated BNP levels) in 9.1% of the patients undergoing PT-Cy-based HCT, with the lowest LVEF at 34%. We found that these patients had equivalent overall survival after HCT in comparison with those without pretransplant cardiomyopathy. Although an assessment of left ventricular diastolic function has not been included as a component of the standard pretransplant workup, we found that the inclusion of pretransplant diastolic dysfunction (grade 2 or worse) as a criterion of pretransplant cardiomyopathy does not affect overall survival. Therefore, our finding that moderate pretransplant cardiomyopathy has no effects on survival adds to the existing literature and supports the idea that PTCy-based HCT can be performed in patients with mildly depressed LVEF values. It should be noted that patients with an LVEF < 34% were not included in the analysis, so the current findings cannot be extrapolated to patients with more severe degrees of left ventricular dysfunction. We found an average posttransplant LVEF reduction of 6 percentage points after PT-Cy-based HCT. The transplant process involves multiple cardiotoxic stimuli, including high-dose chemotherapy (especially cyclophosphamide in PT-Cy) and radiation. The equivalent degree of change in patients undergoing haploidentical HCT and matched HCT with PT-Cy (data not shown) suggests that decrements in LVEF result from the transplant process rather than HLA mismatch and resultant alloreactivity. This notion is supported by the finding of frequent posttransplant systolic dysfunction in adult lymphoma patients who have undergone autologous HCT. 22 HCT survivors are known to have an increased risk of developing cardiomyopathy in comparison with the general population, and these patients suffer from a poorer prognosis. 23 This notion is supported by our finding of decreased overall survival for patients developing posttransplant cardiomyopathy. Conditioning cyclophosphamide and TBI have been identified as risk factors for early heart failure. 23 Although cardiotoxicity has been classically described as a side effect of cyclophosphamide, 8, 24 its incidence in the setting of PT-Cy has not been investigated. In our cohort, 21.9% of the patients developed cardiomyopathy after transplantation. The majority of these cardiomyopathies (94.3%) occurred in the setting of an infectious milieu, with severe sepsis, septic shock, or neutropenic fever during the index hospitalization. Furthermore, 21 of these patients (60%) died within 1 month of the index cardiomyopathy event, whereas among the 14 patients who survived more than 1 month after the index cardiomyopathy event, 9 (64%) subsequently had documented resolution of their cardiomyopathy. In comparison, we found that patients treated with MUD HCT without PT-Cy had a comparable incidence of posttransplant cardiomyopathy. Therefore, the cardiomyopathy reported here likely represents transient, reversible sepsis-associated cardiomyopathy. The incidence of true chronic heart failure due to PT-Cy is likely much less than 25%.
A body of literature has established predictors of cardiovascular events after transplantation, including demographic factors (age and female sex), traditional cardiovascular risk factors (hypertension, diabetes, dyslipidemia, and obesity), and cancer-related factors (chemotherapy, anthracycline exposure, and radiation exposure). 23, 25 Our multivariate analysis revealed that age and diabetes, but not other traditional cardiovascular risk factors, predict posttransplant cardiomyopathy. A history of diabetes may be supplanted by the HCT-CI score, which incorporates a history of diabetes. These findings strongly suggest that cancer-related factors may be more predictive of posttransplant cardiomyopathy. Future research is needed to delineate predictors of cardiovascular toxicities in patients receiving PT-Cy.
We have reported pericardial effusion in 24 patients (13.6%) receiving PT-Cy; 2 (1.1%) had echocardiographic evidence of pericardial tamponade, whereas 1 (0.7%) required draining. The incidence of effusion overall is similar to a previous report of a 16 .9% rate of pericardial effusion for pediatric HCT patients. 26 The incidence of pericardial effusions causing pericardial tamponade (1.1%) is also similar to the previously reported incidence of 1.16%. 27 This study is limited by its single-center design, lack of long-term follow-up, and retrospective nature; hence, further validation and studies are required. Posttransplant echocardiography studies were obtained on an as-needed basis but not for all patients, and this may have introduced a selection bias reflective of local practice patterns. Future inclusion of routine posttransplant echocardiography in the transplant protocol will be needed to address this issue. Finally, the baseline demographic data, risk factors, and ascertainment of death were limited to what was available in the medical records.
In conclusion, we report the incidence of pretransplant and posttransplant cardiomyopathy in a cohort of 176 patients receiving PT-Cy-based HCT. Mild pretransplant LVEF depression was not associated with inferior overall survival. Posttransplant cardiomyopathy correlated with reduced overall survival, although most of these posttransplant cardiomyopathies occurred in the setting of an infectious milieu, and most appeared reversible in patients who survived more than 1 month after the index cardiomyopathy. Age and diabetes, but not other traditional cardiovascular risk factors, predicted the occurrence of posttransplant cardiomyopathy. In comparison with an age-and sex-matched cohort undergoing MRD HCT without PT-Cy, the incidence of posttransplant
